Evidence map›Paper›PMID 17679633›Full record

Trial reportArchives of general psychiatry2007

Preventing depression in age-related macular degeneration.

Barry W Rovner, Robin J Casten, Mark T Hegel, Benjamin E Leiby, William S Tasman

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Archives of general psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00042211 (Preventing Depression in Macular Degeneration), which is not on this map. Cited by 62 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 5 pooled it
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00042211 phase3completednot on this map

Preventing Depression in Macular Degeneration

TypeinterventionalSponsorThomas Jefferson UniversityRan2001 to 2006Enrolled206ConditionsDepression, Macular DegenerationArmsProblem Solving Treatment, Control
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 5 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prevention of depression in adults with long-term physical conditions.The Cochrane database of systematic reviews · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Effects of Vitamin DThe Journal of clinical psychiatry · 2023
    Trial
  7. Depression Agency-Based Collaborative: Effect of Problem-Solving Therapy on Risk of Common Mental Disorders in Older Adults With Home Care Needs.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2019
    Trial
  8. Trial
  9. Measuring Participant Effort in a Depression Prevention Trial: Who Engages in Problem-Solving Therapy?The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2017
    Trial
  10. Trial
  11. Design and Implementation of an Intervention Development Study: Retaining Cognition While Avoiding Late-Life Depression (ReCALL).The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Trial
  12. Design and Recruitment for a Randomized Controlled Trial of Problem-Solving Therapy to Prevent Depression among Older Adults with Need for Supportive Services.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Barry W RovnerDepartment of Psychiatry, Jefferson Hospital for Neuroscience, 900 Walnut St, 4th Floor, Philadelphia, PA 19107, USA. barry.rovner@jefferson.edu
Robin J Casten
Mark T Hegel
Benjamin E Leiby
William S Tasman
Jefferson Hospital for Neuroscience · US

Funding

Improving Function In Age-Related Macular DegenerationU01EY015839 · NEI · THOMAS JEFFERSON UNIVERSITY · PI ROVNER, BARRY W. · 2005 to 2009
$3.9M
PREVENTING DEPRESSION IN MACULAR DEGENERATIONR01MH061331 · NIMH · THOMAS JEFFERSON UNIVERSITY · PI ROVNER, BARRY W · 2001 to 2005
$2.4M
Renal &Urologic Biostatistics Training GrantT32DK060455 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SHULTS, JUSTINE · 2003 to 2019
$1.9M
NEI NIH HHS U01 EY 015839NEI NIH HHS U01 EY015839NIDDK NIH HHS T32 DK060455NIMH NIH HHS R01 MH061331NIMH NIH HHS R01 MH61331
6 · The paper itself

Abstract

contextAge-related macular degeneration is a prevalent disease of aging that may cause irreversible vision loss, disability, and depression. The latter is rarely recognized or treated in ophthalmologic settings.

objectiveTo determine whether problem-solving treatment can prevent depressive disorders in patients with recent vision loss.

designRandomized, controlled trial.

settingOutpatient ophthalmology offices in Philadelphia, Pennsylvania. PATIENTS: Two hundred six patients aged 65 years or older with recent diagnoses of neovascular age-related macular degeneration in one eye and pre-existing age-related macular degeneration in the fellow eye.

interventionPatients were randomly assigned to problem-solving treatment (n = 105) or usual care (n = 101). Problem-solving treatment therapists delivered 6 sessions during 8 weeks in subjects' homes.

main outcome measuresOutcomes were assessed at 2 months for short-term effects and 6 months for maintenance effects. These included DSM-IV-defined diagnoses of depressive disorders, National Eye Institute Vision Function Questionnaire-17 scores, and rates of relinquishing valued activities.

resultsThe 2-month incidence rate of depressive disorders in problem-solving-treated subjects was significantly lower than controls (11.6% vs 23.2%, respectively; odds ratio, 0.39; 95% confidence interval, 0.17-0.92; P = .03). Problem-solving treatment also reduced the odds of relinquishing a valued activity (odds ratio, 0.48; 95% confidence interval, 0.25-0.96; P = .04). This effect mediated the relationship between treatment group and depression. By 6 months, most earlier observed benefits had diminished, though problem-solving treatment subjects were less likely to suffer persistent depression (chi2(1,3) = 8.46; P = .04).

conclusionsProblem-solving treatment prevented depressive disorders and loss of valued activities in patients with age-related macular degeneration as a short-term treatment, but these benefits were not maintained over time. Booster or rescue treatments may be necessary to sustain problem-solving treatment's preventative effect. This study adds important new information to the emerging field of enhanced-care models to prevent or treat depression in older persons.

trial registrationclinicaltrials.gov Identifier: NCT00042211.

Indexed as

Problem SolvingActivities of Daily LivingAmbulatory CareBehavior TherapyComorbidityDiagnostic and Statistical Manual of Mental DisordersHome Care ServicesHumansIncidenceMacular DegenerationMajor Depressive DisorderPsychiatric Status Rating ScalesSurveys and QuestionnairesTreatment OutcomeVision Disorders

Identifiers

PMID17679633
OpenAlexW2149105567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.